GlassScriptPhysician profile
Christine Sung
NPI 1316532872
$5,748.53
in general payments reported to CMS, 2019-2025
26 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $861 · 2023: $1,100 · 2024: $1,672 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.51 |
| Education | $283.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.94 | 2021-2025 | |
| Lilly USA, LLC | $675.12 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $653.43 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $617.18 | 2021-2025 | Ilumya |
| Incyte Corporation | $404.69 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $354.08 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $334.01 | 2023-2025 | |
| Ucb, INC. | $320.51 | 2022-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $311.58 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $156.73 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $150.20 | 2022-2024 | |
| Pfizer INC. | $146.11 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.31 | 2023 | Spevigo |
| Janssen Scientific Affairs, LLC | $114.45 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.55 | 2021-2025 | Jublia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $90.73 | 2023-2025 | Zoryve |
| Amgen INC. | $54.93 | 2023-2024 | Otezla |
| Leo Pharma INC. | $49.70 | 2022-2023 | Adbry |
| Dermavant Sciences, INC. | $33.01 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $29.14 | 2024 | Idacio |
| Strata Skin Sciences, INC. | $24.63 | 2023 | Xtrac |
| Organogenesis INC. | $22.17 | 2024 | Nushield |
| Lnhc, INC | $21.80 | 2025 | Zelsuvmi |
| Almirall LLC | $19.31 | 2024 | Klisyri |
| Organon LLC | $19.01 | 2025 | Vtama |
| Smith+Nephew, INC. | $16.21 | 2024 | Grafix Pl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.